Next Gen Clinical Policies - ODM Provisional Approval
Medicaid Clinical - ODM
Policy Name | Policy # | Approval Date |
---|---|---|
Genet aorto conn (PDF) | BU_V2-2023-1 | 07-01-2023 |
BU_V2.2023-2 | 07-01-2023 | |
BU_V2.2023-3 | 07-01-2023 | |
BU_V2.2023-4 | 07-01-2023 | |
BU_V2.2023-5 | 07-01-2023 | |
BU_V2-2023-6 | 07-01-2023 | |
BU_V2.2023-7 | 07-01-2023 | |
BU_V2-2023-8 | 07-01-2023 | |
BU_V2-2023-9 | 07-01-2023 | |
BU_V2-2023-10 | 07-01-2023 | |
BU_V2-2023-11 | 07-01-2023 | |
BU_V2-2023-12 | 07-01-2023 | |
BU_V2-2023-13 | 07-01-2023 | |
BU_V2-2023-14 | 07-01-2023 | |
BU_V2-2023-15 | 07-01-2023 | |
BU_V2-2023-16 | 07-01-2023 | |
BU_V2-2023-17 | 07-01-2023 | |
BU_V2-2023-18 | 07-01-2023 | |
BU_V2-2023-19 | 07-01-2023 | |
BU_V2-2023-20 | 07-01-2023 | |
BU_V2-2023-21 | 07-01-2023 | |
BU_V2-2023-22 | 07-01-2023 | |
BU_V2-2023-23 | 07-01-2023 | |
BU_V2-2023-24 | 07-01-2023 | |
BU_V2-2023-25 | 07-01-2023 | |
BU_V2-2023-26 | 07-01-2023 | |
BU_V2-2023-27 | 07-01-2023 |
BH Clinical - ODM Prov Apprl
Policy Title | Policy # | Reviewed Date |
---|---|---|
Applied Behavior Analysis (PDF) Applied Behavior Analysis Addendum (PDF) | CP.BH.104 CP.BH.104_Addendum | 13-Jan-23 |
Biofeedback for Behavioral Health Disorders (PDF) | CP.BH.300 | 13-Jan-23 |
Deep Transcranial Magnetic Stimulation (PDF) | CP.BH.201 | 13-Jan-23 |
Institutions for Mental Disease (IMD) Policy (PDF) Institutions for Mental Disease (IMD) Policy Addendum (PDF) | CC.BH.UM.12 CC.BH.UM.12_ Addendum | |
Substance Use and Treatment Services (PDF) | CP.BH.100 | 13-Jan-23 |
Transcranial Magnetic Stimulation (PDF) | CP.BH.200 | 13-Jan-23 |
CP.PHAR.230 | |
CP.PHAR.242 | |
CP.PHAR.468 | |
CP.PHAR.184 | |
CP.PHAR.158 | |
CP.PHAR.243 | |
CP.PHAR.160 | |
CP.PHAR.551 | |
CP.PHAR.506 | |
CP.PHAR.362 | |
CP.PHAR.88 | |
CP.PHAR.553 | |
CP.PHAR.592 | Beremagene geperpavec-svdt (Vyjuvek) |
CP.PHAR.300 | |
CP.PHAR.486 | |
CP.PHAR.417 | |
CP.PHAR.472 | |
CP.PHAR.445 | |
CP.PHAR.416 | |
CP.PHAR.470 | |
CP.PHAR.449 | |
CP.PHAR.146 | |
CP.PHAR.58 | |
CP.PHAR.336 | |
CP.PHAR.97 | |
CP.PHAR.343 | |
CP.PHAR.555 | Efgartigimod Alfa-fcab, Efgartigimod/Hyaluronidase-qvfc (Vyvgart, Vyvgart Hytrulo) (PDF) |
CP.PHAR.419 | |
CP.PHAR.489 | |
CP.PHAR.379 | |
CP.PHAR.288 | |
CP.PHAR.511 | |
CP.PHAR 234 | |
CP.PHAR.453 | |
CP.PHAR.172 | |
CP.PHAR.517 | Human Growth Hormone (Somapacitan, Somatrogon, Somatropin) (PDF) |
CP.PHAR.05 | |
CP.PHAR.189 | |
CP.PHAR.481 | |
CP.PHAR.103 | |
CP.PHAR.568 | |
CP.PHAR.231 | |
CP.PHAR.254 | Infliximab, Infliximab-axxq. Inflismab-dyyb, Infiximab-abda (PDF) |
CP.PHAR.596 | |
CP.PHAR. 367 | |
CP.PHAR.173 | |
CP.PHAR.539 | |
CP.PHAR.558 | |
CP.PHAR.258 | |
CP.PHAR.559 | |
CP.PHAR.259 | |
CP.PHAR.327 | |
CP.PHAR.335 | |
CP.PHAR.528 | |
CP.PHAR 360 | |
CP.PHAR.232 | |
CP.PHAR.536 | |
CP.PHAR.583 | Pacritinib (Vonjo) (PDF) |
CP.PHAR.16 | |
CP.PHAR.332 | |
CP.PHAR.395 | |
CP.PHAR.185 | |
CP.PHAR.115 | |
CP.PHAR.186 | |
CP.PHAR.415 | |
CP.PHAR.223 | |
CP.PHAR.629 | Retifanlimab-dlwr (Zynyz) (PDF) |
CP.PHAR.233 | |
CP.PHAR.570 | Ropeginterferpm Alfa-2b-njft (BESREMi) (PDF) |
CP.PHAR.329 | |
CH.PHAR.606 | Spesolimab-sbzo (Spevigo) (PDF) |
CP.PHAR 409 | |
CP.PHAR.465 | |
CP.PHAR.361 | |
CP.PHAR.591 | |
CP.PHAR. 175 | |
CP.PHARM.621 | |
CP.PHAR.443 | |
CP.PHAR.265 | |
CP.PHAR.187 | |
CP.PHAR.484 | |
CP.PHAR.372 |